Loading…
Relay Therapeutics, Inc. is projected to rise to $24.08 by 2027, a +19% move from its current price of $20.23. RLAY is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $19.54 | $20.23 | $20.95 | +0.05% |
| Jul 14 | $19.27 | $20.24 | $21.27 | +0.09% |
| Jul 15 | $19.06 | $20.25 | $21.52 | +0.14% |
| Jul 16 | $18.89 | $20.26 | $21.73 | +0.18% |
| Jul 17 | $18.75 | $20.27 | $21.92 | +0.23% |
| Jul 18 | $18.62 | $20.28 | $22.09 | +0.27% |
| Jul 19 | $18.50 | $20.29 | $22.26 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $18.50 | $20.29 | $22.26 | +0.32% |
| Week 2 | $17.86 | $20.35 | $23.20 | +0.64% |
| Week 3 | $17.40 | $20.42 | $23.97 | +0.96% |
| Week 4 | $17.02 | $20.48 | $24.65 | +1.28% |
| Week 5 | $16.71 | $20.55 | $25.27 | +1.60% |
| Week 6 | $16.44 | $20.62 | $25.86 | +1.93% |
| Week 7 | $16.19 | $20.68 | $26.41 | +2.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer.
The company has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc.
for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc.
and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Relay Therapeutics, Inc. trades in the Healthcare category and currently sits with a price of $20.75 per share and a market capitalization of $4.52B. It is ranked 1456 in market capitalization. The stock shows a bullish longer-term potential, supported by a multi-year forecast that envisions meaningful upside through 2050.
Near-term figures illustrate a base around the current level with growing expectations across subsequent years, highlighted by progressive avg prices and sizable ROI in later years. These estimates are not guarantees but provide a view of potential price trajectories over time.
A major floor 53.8% below — a decisive break under it would weaken the trend.
The nearest floor, 33.3% below — buyers have tended to step in here.
Price is pressing into resistance (2.6% away) — a breakout level to watch.
A major ceiling 25.3% above — clearing it would confirm fresh momentum.
Key RLAY support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RLAY market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $19.80 | Buy | $19.80 | Buy |
| MA 10 | $19.24 | Buy | $19.15 | Buy |
| MA 20 | $17.68 | Buy | $17.98 | Buy |
| MA 50 | $15.11 | Buy | $15.89 | Buy |
| MA 100 | $13.38 | Buy | $13.82 | Buy |
| MA 200 | $10.33 | Buy | $11.24 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 66.30 | Neutral |
| Stoch RSI (14) | 30.19 | Neutral |
| CCI (20) | 95.94 | Neutral |
| Williams %R (14) | -21.47 | Info |
| MACD (12,26,9) | 0.16 | Buy |
| ROC (12) | 14.71 | Buy |
| Bollinger %B (20,2) | 0.80 | Neutral |
| Stochastic %K (14) | 78.53 | Neutral |
| TRIX (15) | 1.23 | Buy |
| Awesome (5,34) | 3.58 | Buy |
| Ultimate (7,14,28) | 65.76 | Neutral |
| Momentum (10) | 2.17 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 20.51 | Sell |
| ADX (14) | 30.62 | Buy |
| ATR (14) | 0.63 | Info |
The 30-day technical picture is bullish in sentiment. RSI14 sits at 70, and the stock faces resistance at $20.75 with a nearby support at $13.49. The SMA50 is $14.97 and the SMA200 is $10.26, framing a constructive backdrop as momentum remains firm.
Over the last 30 days, the price range has traded between $16.46 and $26.16, capturing a broad swing in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.35 | $20.23 | $26.20 | 0% | Neutral | |
| $18.67 | $24.08 | $33.15 | +19% | Neutral | |
| $21.82 | $29.19 | $42.05 | +44% | Bullish | |
| $29.66 | $40.93 | $61.08 | +102% | Bullish | |
| $33.42 | $47.41 | $72.86 | +134% | Bullish | |
| $35.61 | $51.79 | $81.67 | +156% | Bullish | |
| $39.21 | $58.38 | $94.19 | +189% | Bullish | |
| $40.14 | $61.12 | $100.67 | +202% | Bullish | |
| $43.41 | $67.51 | $113.33 | +234% | Bullish | |
| $52.43 | $83.21 | $142.16 | +311% | Bullish | |
| $74.08 | $129.20 | $237.46 | +539% | Bullish | |
| $154.05 | $318.05 | $649.30 | +14.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $7.35 | $20.23 | $24.39 | +0.00% |
| August 2026 | $17.04 | $20.27 | $24.87 | +0.23% |
| September 2026 | $17.56 | $21.08 | $26.23 | +4.00% |
| October 2026 | $17.74 | $21.46 | $27.02 | +1.80% |
| November 2026 | $16.98 | $20.67 | $26.28 | -3.68% |
| December 2026 | $16.67 | $20.43 | $26.20 | -1.19% |
Click any year to see its month-by-month RLAY forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, RLAY could reach as high as $26.20, with a base case around $20.23 and support toward $7.35 — roughly 0% from $20.23. A consolidation phase looks the most probable path here.
Expect RLAY to range from $18.67 to $33.15 through 2027. The $24.08 average target implies a +19% move from current prices. That is up +19% on the projected 2026 average. Price action looks broadly range-bound.
The RLAY price prediction for 2028 points to an average of $29.19 (low $21.82, high $42.05) — a potential gain of +44% on today's $20.23. Buyers look set to stay in control over this stretch.
In 2029, RLAY is projected to trade between $29.66 and $61.08, averaging $40.93 — a potential gain of +102% from today's $20.23. That is up +40% on the projected 2028 average. Momentum favours further upside here.
Relay Therapeutics, Inc.'s 2030 outlook centres on $47.41, within a $33.42 to $72.86 range. That is up +16% on the projected 2029 average. That marks a +134% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, RLAY could reach as high as $81.67, with a base case around $51.79 and support toward $35.61 — roughly +156% from $20.23. Momentum favours further upside here.
Expect RLAY to range from $39.21 to $94.19 through 2032. The $58.38 average target implies a +189% move from current prices. That is up +13% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The RLAY price prediction for 2033 points to an average of $61.12 (low $40.14, high $100.67) — a potential gain of +202% on today's $20.23. Momentum favours further upside here.
In 2034, RLAY is projected to trade between $43.41 and $113.33, averaging $67.51 — a potential gain of +234% from today's $20.23. That is up +10% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Relay Therapeutics, Inc.'s 2035 outlook centres on $83.21, within a $52.43 to $142.16 range. That is up +23% on the projected 2034 average. That marks a +311% change versus current levels. Momentum favours further upside here.
By 2040, RLAY could reach as high as $237.46, with a base case around $129.20 and support toward $74.08 — roughly +539% from $20.23. Buyers look set to stay in control over this stretch.
Expect RLAY to range from $154.05 to $649.30 through 2050. The $318.05 average target implies a +14.7x move from current prices. That is up +146% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in RLAY today (≈ 49.443758 RLAY) could be worth
$15,725.81
+$14,725.81 (+1473%) by 2050 · US Dollar
Based on the average projected RLAY price of $318.05 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RLAYwould be worth at today's price.
$1,000 invested in RLAY on Jul 10, 2025 (≈ 268.096513 RLAY) would be worth
$5,422.25
+$4,422.25 (+442.2%) today · 5.42× · US Dollar
Based on a RLAY entry price of $3.73 vs. today's $20.23.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $18.65 | $1,084.45 | +8.4% |
| 1 month ago | $13.49 | $1,499.26 | +49.9% |
| 3 months ago | $14.94 | $1,353.75 | +35.4% |
| 6 months ago | $7.8 | $2,592.95 | +159.3% |
| 1 year ago | $3.73 | $5,422.25 | +442.2% |
| All time (5.0y) ago | $33.79 | $598.55 | -40.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RLAY forecast.
Our base-case forecast reaches $40.00 around 2029.
Implied market cap at $40.00: $8.72B
The multi-year forecast shows sustained upside, starting with the 2026 outlook at an average of $20.75 and a neutral stance. The model projects continued gains with an average price of $48.02 by 2030 and a bullish sentiment through the period. By 2030, the forecast calls for an average price of $48.02 with a return on investment of 131.4%.
Looking further ahead, the 2040 forecast envisions an average of $128.69 and a ROI of 520.2%, with the sentiment marked as bullish. By 2050, the average price is forecast to be $315.59, with a max of $645.64 and a ROI of 1420.9%, still labeled bullish. The path includes higher annualized volatility (70%), reflecting a wide potential range and uncertainty inherent in long-horizon estimates.
These figures are estimates, not guarantees, and should be considered within the broader risk context of healthcare biotechnology equities.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $48.02 with a max of $73.90 and a min of $33.82, and a forecasted ROI of 131.4%; sentiment is bullish.
Forecasts show bullish sentiment in 2027 onward with rising averages and ROIs, including 131.4% in 2030, 520.2% by 2040, and 1420.9% by 2050; 2026 is neutral. These are estimates, not guarantees, and depend on market and company-specific factors.
Yes. The 2033 max forecast is $101.36, and the 2034 max forecast is $113.77, indicating potential to exceed $100 in those years.
Current price is $20.75 per share and the market capitalization is $4.52B.
For 2040, the average price is $128.69 with a max of $236.95 and a ROI of 520.2%. For 2050, the average price is $315.59 with a max of $645.64 and a ROI of 1420.9%.
Relay Therapeutics, Inc. Community Discussion
0Share your Relay Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.